LPCAT3

Across TCGA pan-cancer cohorts, LPCAT3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LPCAT3 data layer compared with 18 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher LPCAT3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LPCAT3 expression acts as an unfavorable survival marker, although some lineages such as LIHC show a favorable association.

STAD, KICH, and UCEC are the cancer types where LPCAT3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.149	0.710	<.001	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	All	1.000	0.282	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LPCAT3–STAD (DFS)

Open the STAD breakdown →